Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 2926-2931

  Lin, Chin Chung ^a   Fang, Che ^a   Benetton, Salete ^a   Xu, Gui Fen ^a   Yeh, Li Tain ^a  

^a Valeant Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYTESTOSTERONE; ADEFOVIR; ADENINE DERIVATIVE; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INDUCING AGENT; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; ENZYME INDUCING AGENT; KETOCONAZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3A4; PRADEFOVIR; TESTOSTERONE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN CELL; LIVER CELL CULTURE; LIVER MICROSOME; LIVER MICROSOME METABOLISM; METABOLIC ACTIVATION; METABOLIC RATE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT; SMALL INTESTINE;

ADENINE; ANIMALS; ANTIBODIES, MONOCLONAL; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DRUG INTERACTIONS; ENZYME INDUCTION; HEPATOCYTES; HUMANS; ISOENZYMES; KETOCONAZOLE; MICROSOMES, LIVER; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RATS;

EID: 33748676891     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01566-05     Document Type: Article

References (20)

1. Balzarini, J., Z. Hao, P. Herdewijn, D. G. Johns, and E. De Clercq. 1991. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88:1499-1503.
2. Bjornsson, T. D., J. T. Callaghan, H. J. Einolf, V. Fischer, L. Gan, S. Grimm, J. Kao, S. P. King, G. Miwa, L. Ni, G. Kumar, J. McLeod, R. S. Obach, S. Roberts, A. Roe, A. Shah, F. Snikeris, J. T. Sullivan, D. Tweedie, J. M. Vega, J. Walsh, and S. A. Wrighton. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31:815-832.
3. Cundy, K. C., P. Barditch-Crovo, R. E. Walker, A. C. Collier, D. Ebeling, J. Toole, and H. S. Jaffe. 1995. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type I-infected patients. Antimicrob. Agents Chemother. 39:2401-2405.
4. Cundy, K. C., J. P. Shaw, and W. Lee. 1994. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys. Antimcrob. Agents Chemother. 38:365-368.
5. Food and Drug Administration. 2002. Adefovir dipivoxil for the treatment of chronic hepatitis B. FDA Advisory Committee brief document NDA 21-449, July 5. Food and Drug Administration, Washington, D.C.
6. i values and impact of CYP3A5 expression. Drug Metab. Dispos. 27:180-187.
7. Hadziyannis, S., N. Tassopoulos, E. Heathcote, T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. Lim, Z. Goodman, M. Wulfsohn, S. Xiong, J. Fry, and C. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
8. Heijtink, R. A., G. A. De Wilde, J. Kruining, L. Berk, J. Balzarini, E. de Clercq, A. Holy, and S. W. Schalm. 1993. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antivir. Res. 21:141-153.
9. Heijtink, R. A., J. Kruining, G. A. De Wilde, J. Balzarini, E. De Clercq, and S. W. Schalm. 1994. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:2180-2182.
10. Kwon, Y. 2001. Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists, p. 221. Kluwer Academic/Plenum Publishers, New York, N.Y.
11. Lin, C. C., C. Xu, A. Teng, L. Yeh, and J. Peterson. 2005. Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. J. Clin. Pharmacol. 45:1250-1258.
12. 14C]remofovir in rats and cynomolgus monkeys. Antimicrob. Agents Chemother. 49:925-930.
13. Lin, C. C., L. T. Yeh, D. Vitarella, Z. Hong, and M. D. Erion. 2004. Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antivir. Chem. Chemother. 15:307-317.
14. Marcellin, P., T. T. Chang, S. Lim, M. Tong, W. Sievert, M. Shiffman, L. Jeffers, Z. Goodman, M. Wulfsohn, S. Xiong, J. Fry, and C. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 349:808-816.
15. Merta, A., J. Vesely, I. Votruba, I. Rosenberg, and A. Holy. 1990. Phosphorylation of acyclic nucleotide analogs HPMPA and PMEA in L1210 mouse leukemia cell extracts. Neoplasma 37:111-120.
16. Omar, G., P. H. Whiting, G. M. Hawksworth, M. J. Humphrey, and M. D. Burke. 1997. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther. Drug Monit. 19:436-445.
17. Paine, M. F., M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel. 1997. Characterization of inter-intestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283:1552-1562.
18. Palu, G., S. Stefanelli, M. Rassu, C. Parolin, J. Balzarini, and E. De Clercq. 1991. Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antivir. Res. 16:115-119.
19. Satoh, T., H. Munakata, K. Fujita, S. Itoh, T. Kamataki, and I. Yoshizawa. 2003. Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol. Pharm. Bull. 26:695-700.
20. Shaw, J. P., M. Louie, V. Krishnamurthy, M. Arimilli, R. Jones, A. Bidgood, W. Lee, and K. Cundy. 1997. Pharmacokientics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 25:362-366.